These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22570399)

  • 21. Untangling the confusion. Alzheimer's management today.
    Wheldon M
    Adv Nurse Pract; 2005 May; 13(5):47-8, 50, 52. PubMed ID: 15898316
    [No Abstract]   [Full Text] [Related]  

  • 22. Behavioral and psychological symptoms assessed with the BEHAVE-AD-FW are differentially associated with cognitive dysfunction in Alzheimer's disease.
    Ito T; Meguro K; Akanuma K; Meguro M; Lee E; Kasuya M; Ishii H; Mori E
    J Clin Neurosci; 2007 Sep; 14(9):850-5. PubMed ID: 17587584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amisulpride in the treatment of behavioural disturbances among patients with moderate to severe Alzheimer's disease.
    Mauri M; Mancioli A; Rebecchi V; Corbetta S; Colombo C; Bono G
    Acta Neurol Scand; 2006 Aug; 114(2):97-101. PubMed ID: 16867031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmas.
    Omerovic M; Hampel H; Teipel SJ; Buerger K
    World J Biol Psychiatry; 2008; 9(1):69-75. PubMed ID: 17886162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.
    Schmitt FA; van Dyck CH; Wichems CH; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):255-62. PubMed ID: 17132970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management strategies for problem behaviors in the patient with dementia.
    Lehninger FW; Ravindran VL; Stewart JT
    Geriatrics; 1998 Apr; 53(4):55-6, 66-8, 71-5. PubMed ID: 9559028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Rivastigmine: a review of its clinical effectiveness].
    Spiegel R
    Rev Neurol; 2002 Nov 1-15; 35(9):859-69. PubMed ID: 12436385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Behavioral problems in dementia. Strategies for pharmacologic and nonpharmacologic management.
    Smith AG
    Postgrad Med; 2004 Jun; 115(6):47-52, 55-6. PubMed ID: 15216573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. APOE-related frequency of cognitive and noncognitive symptoms in dementia.
    Cacabelos R; Rodríguez B; Carrera C; Caamaño J; Beyer K; Lao JI; Sellers MA
    Methods Find Exp Clin Pharmacol; 1996 Dec; 18(10):693-706. PubMed ID: 9121226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The basis for disease-modifying treatments for Alzheimer's disease: the Sixth Annual Mild Cognitive Impairment Symposium.
    Duara R; Barker W; Loewenstein D; Bain L
    Alzheimers Dement; 2009 Jan; 5(1):66-74. PubMed ID: 19118811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effective nursing interventions for the management of Alzheimer's disease.
    Maier-Lorentz MM
    J Neurosci Nurs; 2000 Jun; 32(3):153-7. PubMed ID: 10907202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
    Campanozzi MD; Casali E; Neviani F; Martini E; Neri M
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():91-6. PubMed ID: 17317439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current treatments for patients with Alzheimer disease.
    Osborn GG; Saunders AV
    J Am Osteopath Assoc; 2010 Sep; 110(9 Suppl 8):S16-26. PubMed ID: 20926739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current issues in dementia pharmacotherapy.
    Daiello LA
    Am J Manag Care; 2007 Dec; 13 Suppl 8():S198-202. PubMed ID: 18095783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
    Cummings JL; Mackell J; Kaufer D
    Alzheimers Dement; 2008 Jan; 4(1):49-60. PubMed ID: 18631950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alzheimer's disease: a review of recent developments.
    Salawu FK; Umar JT; Olokoba AB
    Ann Afr Med; 2011; 10(2):73-9. PubMed ID: 21691010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current treatments for Alzheimer's disease: cholinesterase inhibitors.
    Doody RS
    J Clin Psychiatry; 2003; 64 Suppl 9():11-7. PubMed ID: 12934969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.